Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

n of response in patients with recurrent NSCLC who are treated with Xcytrin. Patients in the trial are randomized to receive either a 10mg/kg dose of Xcytrin every week, or a 15mg/kg dose every three weeks. Tumor response rate is being evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), the standard parameters used to document response for solid tumors.

Of 58 evaluable patients there was a confirmed response rate of 5.2%, or three partial responses. Twenty patients (34.5%) had stable disease. One of the responders received Xcytrin after having progressed through two prior lines of therapy: carboplatin, gemcitabine and bevacizumab, followed by erlotinib. The other two had previously failed either carboplatin/gemcitabine or cisplatin/vinorelbine. Median time to progression was seven weeks for all patients. Twenty (34.5%) patients received four or more cycles of Xcytrin, of whom seven did not respond to first line chemotherapy. Thirteen percent were free from progression at six months. Median survival was eight months, with 62% and 30% of patients alive at 6 and 12 months, respectively. Xcytrin was well-tolerated in this study. The most common grade 3 or 4 adverse events were hypophosphatemia (24%), dyspnea (12%), fatigue (10%), hypoxia (7%), and finger blisters (5%).

About Non-Small Cell Lung Cancer

The American Cancer Society predicts that there will be more than 213,000 new cases of lung cancer in the U.S. in 2007. Lung cancer is the leading cause of cancer death, and accounts for over 160,000 deaths in the U.S. each year. The most common form of lung cancer, non-small cell, is incurable in advanced stages. Lung cancer frequently spreads to other body parts, including the brain.

Xcytrin in Second-Line Lung Cancer

Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/19/2014)... , December 18, 2014 ... application/module that is used to store, manipulate, and ... comprises a patient tracking and scheduling system, result ... of RIS with HIS and other databases improves ... registration and patient scheduling, patient list management, radiology ...
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... July 25, 2011 A leading international scientist in ... ask their dentists about the potential for cross-contamination in ... that fasten patients, protective bibs in place. ... Dr. John Molinari, Director of Infection Control for ...
... Prasco Laboratories, the Authorized Generics company, announced today it has signed ... the terms of the agreement, Prasco will ... Generic version of Ponstel ® . Prasco ... Prasco label. "With the introduction of the authorized ...
Cached Medicine Technology:Question Your Dentist About Potential for Cross-Contamination, Leading Infection-Control Scientist Tells Fox News 2Prasco® Announces Authorized Generic Agreement with Shionogi Inc. 2
(Date:12/21/2014)... Theme and plugin developers ... plugin for Final Cut Pro X entitled ProMotion. , ... more with absolute ease.” Said Christiana Austin, CEO of ... needed to easily animate their media inside FCPX.” , ... users to animate pictures, videos, logos, and more with ...
(Date:12/21/2014)... Downey, CA (PRWEB) December 21, 2014 The ... toy drive in the Santa Ana and Whittier offices. The ... help brighten the lives of patients and their families during ... to reach out to approximately 70 children between both offices. ... With the help of Target’s community service team, store managers ...
(Date:12/20/2014)... December 21, 2014 BambooIndustry.com is ... Recently, the business has announced its bamboo flooring ... the best material from certified suppliers, and offers ... customers worldwide. In the current promotion, all customers ... off, when they say they know BambooIndustry.com from ...
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... The print component of Healthy Aging is distributed within ... copies and an estimated readership of 420,000. The digital ... strategy and across a network of top news sites ... the campaign, click here . , The publication ... CTV’s The Social. Lainey Lui, Melissa Grelo, Traci ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
... About ten years ago, the discovery of microRNAs ― ... unlocked a world of scientific possibilities, including a deeper ... "deep sequencing," which gives scientists the ability to discover ... Now, Tel Aviv University researchers have developed the cutting-edge ...
... departments when they,ve broken a leg, been stabbed or ... the Stanford University School of Medicine finds that 90 ... The high prevalence was surprising, said M. Kit Delgado, ... at Stanford,s Center for Primary Care and Outcomes Research, ...
... in daycare puts children with a chronic lung condition ... infections, according to a study from Johns Hopkins Children,s ... . The researchers say their findings should ... of age, for signs of lung disease and to ...
... HealthDay Reporter , SATURDAY, Sept. 25 (HealthDay News) ... as much water as they should, and the deficiency ... "Even mild dehydration can affect physiological function, and cause ... Heller, clinical nutrition coordinator at the Center for Cancer ...
... Lillian Feldshuh, of Scarsdale, NY, an early recipient of ... Patient Award yesterday at the Transcatheter Cardiovascular Therapeutics (TCT ... a success and Feldshuh, who will turn 100 years ... In 2006, Lillian Feldshuh suffered from aortic stenosis, a ...
... of the major disease states in the developed world. But ... You may experience stress as something that affects your entire ... if we zoom in on the building bricks of the ... differently. Stress can arise at the cellular level after exposure ...
Cached Medicine News:Health News:Diving deeper into the gene pool 2Health News:Preventive care poses dilemma for emergency departments, Stanford study finds 2Health News:Preventive care poses dilemma for emergency departments, Stanford study finds 3Health News:Daycare puts children with lung disease at risk for serious illness 2Health News:U.S. Kids Drink Too Little Water: Study 2Health News:U.S. Kids Drink Too Little Water: Study 3Health News:Stress can control our genes 2
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... 4 precisely angled 64° mirrors to deliver ... chamber angle with slight rotation. The ... provides a stable platform during laser treatment ... lens provides a complete view of the ...
... the versatility that a second mirror adds, then ... trabeculum. It features the same 1.5x magnification as ... at 60 and 64 respectively. Available in standard ... recommends the "Flanged" model for laser use. ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
Medicine Products: